120 related articles for article (PubMed ID: 9561111)
1. Characterization of A-93178, an iminoxy-quinoline inhibitor of leukotriene biosynthesis.
Bell RL; Harris RR; Bouska JB; Hulkower KI; Moore J; Bhatia P; Malo PE; Kalosa T; Brooks CD; Carter GW
Adv Exp Med Biol; 1997; 433():91-4. PubMed ID: 9561111
[No Abstract] [Full Text] [Related]
2. Quinolines as potent 5-lipoxygenase inhibitors: synthesis and biological profile of L-746,530.
Dubé D; Blouin M; Brideau C; Chan CC; Desmarais S; Ethier D; Falgueyret JP; Friesen RW; Girard M; Girard Y; Guay J; Riendeau D; Tagari P; Young RN
Bioorg Med Chem Lett; 1998 May; 8(10):1255-60. PubMed ID: 9871745
[TBL] [Abstract][Full Text] [Related]
3. Ionophore A23187-induced leukotriene biosynthesis in equine granulocytes-neutrophils, but not eosinophils require exogenous arachidonic acid.
Lindberg A; Tornhamre S; Mugnai S; Lindgren J
Biochim Biophys Acta; 1998 Mar; 1391(2):247-55. PubMed ID: 9555040
[TBL] [Abstract][Full Text] [Related]
4. Medicinal plants from nepal: evaluation as inhibitors of leukotriene biosynthesis.
Kumar S; Ziereis K; Wiegrebe W; Müller K
J Ethnopharmacol; 2000 Jun; 70(3):191-5. PubMed ID: 10837982
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of indolylalkoxyiminoalkylcarboxylates as leukotriene biosynthesis inhibitors.
Kolasa T; Bhatia P; Brooks CD; Hulkower KI; Bouska JB; Harris RR; Bell RL
Bioorg Med Chem; 1997 Mar; 5(3):507-14. PubMed ID: 9113329
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.
Tagari P; Brideau C; Chan C; Frenette R; Black C; Ford-Hutchinson A
Agents Actions; 1993 Sep; 40(1-2):62-71. PubMed ID: 8147271
[TBL] [Abstract][Full Text] [Related]
7. Activation of leukotriene synthesis in human neutrophils by exogenous arachidonic acid: inhibition by adenosine A(2a) receptor agonists and crucial role of autocrine activation by leukotriene B(4).
Surette ME; Krump E; Picard S; Borgeat P
Mol Pharmacol; 1999 Nov; 56(5):1055-62. PubMed ID: 10531413
[TBL] [Abstract][Full Text] [Related]
8. Platelets, neutrophils, and vasoconstriction after arterial injury by angioplasty in pigs: effects of MK-886, a leukotriene biosynthesis inhibitor.
Provost P; Borgeat P; Merhi Y
Br J Pharmacol; 1998 Jan; 123(2):251-8. PubMed ID: 9489613
[TBL] [Abstract][Full Text] [Related]
9. Effect of FLAP antagonist MK-0591 on leukotriene production and ozone-induced airway responses in dogs.
Stevens WH; Lane CG; Woolley MJ; Ellis R; Tagari P; Black C; Ford-Hutchinson A; O'Byrne PM
J Appl Physiol (1985); 1994 Apr; 76(4):1583-8. PubMed ID: 8045835
[TBL] [Abstract][Full Text] [Related]
10. A-78773: a selective, potent 5-lipoxygenase inhibitor.
Bell RL; Brooks DW; Young PR; Lanni C; Stewart AO; Bouska J; Malo PE; Carter GW
J Lipid Mediat; 1993; 6(1-3):259-64. PubMed ID: 8395248
[TBL] [Abstract][Full Text] [Related]
11. A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.
Prasit P; Belley M; Blouin M; Brideau C; Chan C; Charleson S; Evans JF; Frenette R; Gauthier JY; Guay J
J Lipid Mediat; 1993; 6(1-3):239-44. PubMed ID: 8357985
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse.
Cunningham FM; Andrews M; Landoni MF; Lees P
J Vet Pharmacol Ther; 1997 Aug; 20(4):296-307. PubMed ID: 9280370
[TBL] [Abstract][Full Text] [Related]
13. The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor.
Bell RL; Bouska J; Young PR; Lanni C; Machinist J; Malo PE; Summers JB; Brooks DW; Carter GW
Agents Actions; 1993 Mar; 38(3-4):178-87. PubMed ID: 8213344
[TBL] [Abstract][Full Text] [Related]
14. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products.
Fischer L; Hornig M; Pergola C; Meindl N; Franke L; Tanrikulu Y; Dodt G; Schneider G; Steinhilber D; Werz O
Br J Pharmacol; 2007 Oct; 152(4):471-80. PubMed ID: 17704828
[TBL] [Abstract][Full Text] [Related]
15. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis.
Fruchtmann R; Mohrs KH; Hatzelmann A; Raddatz S; Fugmann B; Junge B; Horstmann H; Müller-Peddinghaus R
Agents Actions; 1993 Mar; 38(3-4):188-95. PubMed ID: 8213345
[TBL] [Abstract][Full Text] [Related]
16. WY-50,295 tromethamine: a novel inhibitor of leukotriene-mediated reactions.
Weichman BM; Berkenkopf JW; Grimes D; Heaslip RJ; Sturm RJ; Chang JY
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():477-80. PubMed ID: 1847784
[No Abstract] [Full Text] [Related]
17. Leukotriene formation by bovine polymorphonuclear leukocytes.
Walstra P; Verhagen J; Veldink GA; Vliegenthart JF
Biochim Biophys Acta; 1984 Oct; 795(3):499-503. PubMed ID: 6089908
[TBL] [Abstract][Full Text] [Related]
18. Natural forms of vitamin E and 13'-carboxychromanol, a long-chain vitamin E metabolite, inhibit leukotriene generation from stimulated neutrophils by blocking calcium influx and suppressing 5-lipoxygenase activity, respectively.
Jiang Z; Yin X; Jiang Q
J Immunol; 2011 Jan; 186(2):1173-9. PubMed ID: 21169551
[TBL] [Abstract][Full Text] [Related]
19. [Pyrrolo(2,3-c)quinolines and pyrrolo(3,4-d)quinolines--synthesis and investigation of lipoxygenase inhibition].
Görlitzer K; Fabian J; Frohberg P; Drutkowski G
Pharmazie; 2002 Apr; 57(4):243-9. PubMed ID: 11998442
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic analysis of a novel leukotriene biosynthesis inhibitor, MK-0591, in healthy volunteers.
Uematsu T; Kanamaru M; Kosuge K; Hara K; Uchiyama N; Takenaga N; Tanaka W; Friedman BS; Nakashima M
Br J Clin Pharmacol; 1995 Jul; 40(1):59-66. PubMed ID: 8527269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
